SEC Form 3 filed by new insider Smith Darren Charlton
$TLX
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ] | |||||||||||||||
| 3a. Foreign Trading Symbol
[TLX] | 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares | 10,810 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Performance Share Appreciation Rights (right to buy) | (1) | 10/24/2027 | Ordinary Shares | 45,449 | $6.15(2) | D | |
| Performance Share Appreciation Rights (right to buy) | (3) | 10/24/2027 | Ordinary Shares | 32,463 | $6.15(2) | D | |
| Performance Share Appreciation Rights (right to buy) | (4) | 12/31/2027 | Ordinary Shares | 88,497 | $6.9(2) | D | |
| Share Rights | (5) | 03/31/2028 | Ordinary Shares | 1,111 | $0 | D | |
| Share Rights | (6) | 03/31/2029 | Ordinary Shares | 14,741 | $0 | D | |
| Explanation of Responses: |
| 1. The performance share appreciation rights (PSARs) were granted on October 24, 2022, and became vested and exercisable on March 6, 2025. |
| 2. Conversion price is reported in Australian Dollars. |
| 3. The PSARs were granted on October 24, 2022 and became vested and exercisable on March 6, 2025. |
| 4. The PSARs were granted on April 25, 2023 and became vested and exercisable on March 12, 2026. |
| 5. The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026. |
| 6. The SRs were granted on March 18, 2026 and will become vested and exercisable in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only, subject to continued service with the issuer. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share. |
| Remarks: |
| Ex. 24 - Power of Attorney |
| /s/ Oliver Newman, on behalf of Mr. Darren Smith, Group CFO | 04/01/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||